Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma

被引：0

作者：

Yoshinori Hoshino

Hirotoshi Hasegawa

Yoshiyuki Ishii

Takashi Endo

Hiroki Ochiai

Koji Okabayashi

Gou Kaneko

Shuji Mikami

Makio Mukai

Mototsugu Oya

Yuko Kitagawa

机构：

[1] Keio University,Department of Surgery, School of Medicine

[2] Keio University,Department of Pathology

[3] Keio University,Department of Urology

来源：

International Journal of Clinical Oncology | 2012年 / 17卷

关键词：

Perforation; Sunitinib; Renal cell carcinoma; Emergency surgery;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials. Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.

引用

页码：412 / 416

页数：4

共 47 条

[1]

Osusky KL(2004)The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels Angiogenesis 7 225-233

[2]

Hallahan DE(2003)SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 471-478

[3]

Fu A(2003)In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327-337

[4]

Abrams TJ(2007)Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 1367-1373

[5]

Lee LB(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124

[6]

Murray LJ(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial Lancet 368 1329-1338

[7]

Mendel DB(2006)Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25-35

[8]

Laird AD(2008)Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment World J Gastroenterol 14 6096-6099

[9]

Xin X(2009)Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma Invest New Drugs 27 83-87

[10]

Goodman VL(1971)Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182-1186

← 1 2 3 4 5 →